Compare AX & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AX | PRAX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.0B |
| IPO Year | 2005 | 2020 |
| Metric | AX | PRAX |
|---|---|---|
| Price | $82.19 | $179.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $96.86 | ★ $228.69 |
| AVG Volume (30 Days) | 266.1K | ★ 926.2K |
| Earning Date | 10-30-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.44 | N/A |
| Revenue | ★ $1,202,571,000.00 | $7,463,000.00 |
| Revenue This Year | $17.36 | N/A |
| Revenue Next Year | $10.34 | $44.43 |
| P/E Ratio | $11.06 | ★ N/A |
| Revenue Growth | 6.69 | ★ 364.98 |
| 52 Week Low | $54.46 | $26.70 |
| 52 Week High | $93.84 | $206.71 |
| Indicator | AX | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 55.13 | 52.85 |
| Support Level | $81.48 | $181.76 |
| Resistance Level | $83.43 | $199.47 |
| Average True Range (ATR) | 2.29 | 14.96 |
| MACD | 0.59 | -3.33 |
| Stochastic Oscillator | 83.01 | 47.05 |
Axos Financial Inc is a bank holding company that operates through its bank subsidiary, BofI Federal Bank, a nationwide bank that provides financing for single and multifamily residential properties, small to medium-size businesses in certain sectors, and selected specialty finance receivables. Its operating segments are banking business segment and securities business segment. The bank distributed its products through a wide range of retail distribution channels, including only banking brands, affinity groups, and sales teams, among others. The majority of the bank's mortgage exposure is titled toward the state of California, particularly its southern region. Net interest income is a majority of the bank's revenue.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.